Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth

Surendra K. Shukla, Aneesha Dasgupta, Kamiya Mehla, Venugopal Gunda, Enza Vernucci, Joshua Souchek, Gennifer Goode, Ryan King, Anusha Mishra, Ibha Rai, Sangeetha Nagarajan, Nina V. Chaika, Fang Yu, Pankaj Singh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancerrelated deaths in the US. Cancer-associated cachexia is present in up to 80% of PDAC patients and is associated with aggressive disease and poor prognosis. In the present studies we evaluated an anti-cancer natural product silibinin for its effectiveness in targeting pancreatic cancer aggressiveness and the cachectic properties of pancreatic cancer cells and tumors. Our results demonstrate that silibinin inhibits pancreatic cancer cell growth in a dose-dependent manner and reduces glycolytic activity of cancer cells. Our LC-MS/MS based metabolomics data demonstrates that silibinin treatment induces global metabolic reprogramming in pancreatic cancer cells. Silibinin treatment diminishes c-MYC expression, a key regulator of cancer metabolism. Furthermore, we observed reduced STAT3 signaling in silibinin-treated cancer cells. Overexpression of constitutively active STAT3 was sufficient to substantially revert the silibinin-induced downregulation of c-MYC and the metabolic phenotype. Our in vivo investigations demonstrate that silibinin reduces tumor growth and proliferation in an orthotopic mouse model of pancreatic cancer and prevents the loss of body weight and muscle. It also improves physical activity including grip strength and latency to fall in tumorbearing mice. In conclusion, silibinin-induced metabolic reprogramming diminishes cell growth and cachectic properties of pancreatic cancer cells and animal models.

Original languageEnglish (US)
Pages (from-to)41146-41161
Number of pages16
JournalOncotarget
Volume6
Issue number38
DOIs
StatePublished - Jan 1 2015

Fingerprint

Cachexia
Pancreatic Neoplasms
Growth
Neoplasms
Adenocarcinoma
Metabolomics
silybin
Hand Strength
Biological Products
Cause of Death
Down-Regulation
Animal Models
Body Weight
Exercise
Phenotype
Muscles
Therapeutics

Keywords

  • C-Myc
  • Cachexia
  • Cancer metabolism
  • Pancreatic cancer
  • Silibinin

ASJC Scopus subject areas

  • Oncology

Cite this

Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. / Shukla, Surendra K.; Dasgupta, Aneesha; Mehla, Kamiya; Gunda, Venugopal; Vernucci, Enza; Souchek, Joshua; Goode, Gennifer; King, Ryan; Mishra, Anusha; Rai, Ibha; Nagarajan, Sangeetha; Chaika, Nina V.; Yu, Fang; Singh, Pankaj.

In: Oncotarget, Vol. 6, No. 38, 01.01.2015, p. 41146-41161.

Research output: Contribution to journalArticle

Shukla, SK, Dasgupta, A, Mehla, K, Gunda, V, Vernucci, E, Souchek, J, Goode, G, King, R, Mishra, A, Rai, I, Nagarajan, S, Chaika, NV, Yu, F & Singh, P 2015, 'Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth', Oncotarget, vol. 6, no. 38, pp. 41146-41161. https://doi.org/10.18632/oncotarget.5843
Shukla SK, Dasgupta A, Mehla K, Gunda V, Vernucci E, Souchek J et al. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Oncotarget. 2015 Jan 1;6(38):41146-41161. https://doi.org/10.18632/oncotarget.5843
Shukla, Surendra K. ; Dasgupta, Aneesha ; Mehla, Kamiya ; Gunda, Venugopal ; Vernucci, Enza ; Souchek, Joshua ; Goode, Gennifer ; King, Ryan ; Mishra, Anusha ; Rai, Ibha ; Nagarajan, Sangeetha ; Chaika, Nina V. ; Yu, Fang ; Singh, Pankaj. / Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. In: Oncotarget. 2015 ; Vol. 6, No. 38. pp. 41146-41161.
@article{c62726597c3e4da0a88a222c767eef9a,
title = "Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancerrelated deaths in the US. Cancer-associated cachexia is present in up to 80{\%} of PDAC patients and is associated with aggressive disease and poor prognosis. In the present studies we evaluated an anti-cancer natural product silibinin for its effectiveness in targeting pancreatic cancer aggressiveness and the cachectic properties of pancreatic cancer cells and tumors. Our results demonstrate that silibinin inhibits pancreatic cancer cell growth in a dose-dependent manner and reduces glycolytic activity of cancer cells. Our LC-MS/MS based metabolomics data demonstrates that silibinin treatment induces global metabolic reprogramming in pancreatic cancer cells. Silibinin treatment diminishes c-MYC expression, a key regulator of cancer metabolism. Furthermore, we observed reduced STAT3 signaling in silibinin-treated cancer cells. Overexpression of constitutively active STAT3 was sufficient to substantially revert the silibinin-induced downregulation of c-MYC and the metabolic phenotype. Our in vivo investigations demonstrate that silibinin reduces tumor growth and proliferation in an orthotopic mouse model of pancreatic cancer and prevents the loss of body weight and muscle. It also improves physical activity including grip strength and latency to fall in tumorbearing mice. In conclusion, silibinin-induced metabolic reprogramming diminishes cell growth and cachectic properties of pancreatic cancer cells and animal models.",
keywords = "C-Myc, Cachexia, Cancer metabolism, Pancreatic cancer, Silibinin",
author = "Shukla, {Surendra K.} and Aneesha Dasgupta and Kamiya Mehla and Venugopal Gunda and Enza Vernucci and Joshua Souchek and Gennifer Goode and Ryan King and Anusha Mishra and Ibha Rai and Sangeetha Nagarajan and Chaika, {Nina V.} and Fang Yu and Pankaj Singh",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.5843",
language = "English (US)",
volume = "6",
pages = "41146--41161",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "38",

}

TY - JOUR

T1 - Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth

AU - Shukla, Surendra K.

AU - Dasgupta, Aneesha

AU - Mehla, Kamiya

AU - Gunda, Venugopal

AU - Vernucci, Enza

AU - Souchek, Joshua

AU - Goode, Gennifer

AU - King, Ryan

AU - Mishra, Anusha

AU - Rai, Ibha

AU - Nagarajan, Sangeetha

AU - Chaika, Nina V.

AU - Yu, Fang

AU - Singh, Pankaj

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancerrelated deaths in the US. Cancer-associated cachexia is present in up to 80% of PDAC patients and is associated with aggressive disease and poor prognosis. In the present studies we evaluated an anti-cancer natural product silibinin for its effectiveness in targeting pancreatic cancer aggressiveness and the cachectic properties of pancreatic cancer cells and tumors. Our results demonstrate that silibinin inhibits pancreatic cancer cell growth in a dose-dependent manner and reduces glycolytic activity of cancer cells. Our LC-MS/MS based metabolomics data demonstrates that silibinin treatment induces global metabolic reprogramming in pancreatic cancer cells. Silibinin treatment diminishes c-MYC expression, a key regulator of cancer metabolism. Furthermore, we observed reduced STAT3 signaling in silibinin-treated cancer cells. Overexpression of constitutively active STAT3 was sufficient to substantially revert the silibinin-induced downregulation of c-MYC and the metabolic phenotype. Our in vivo investigations demonstrate that silibinin reduces tumor growth and proliferation in an orthotopic mouse model of pancreatic cancer and prevents the loss of body weight and muscle. It also improves physical activity including grip strength and latency to fall in tumorbearing mice. In conclusion, silibinin-induced metabolic reprogramming diminishes cell growth and cachectic properties of pancreatic cancer cells and animal models.

AB - Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancerrelated deaths in the US. Cancer-associated cachexia is present in up to 80% of PDAC patients and is associated with aggressive disease and poor prognosis. In the present studies we evaluated an anti-cancer natural product silibinin for its effectiveness in targeting pancreatic cancer aggressiveness and the cachectic properties of pancreatic cancer cells and tumors. Our results demonstrate that silibinin inhibits pancreatic cancer cell growth in a dose-dependent manner and reduces glycolytic activity of cancer cells. Our LC-MS/MS based metabolomics data demonstrates that silibinin treatment induces global metabolic reprogramming in pancreatic cancer cells. Silibinin treatment diminishes c-MYC expression, a key regulator of cancer metabolism. Furthermore, we observed reduced STAT3 signaling in silibinin-treated cancer cells. Overexpression of constitutively active STAT3 was sufficient to substantially revert the silibinin-induced downregulation of c-MYC and the metabolic phenotype. Our in vivo investigations demonstrate that silibinin reduces tumor growth and proliferation in an orthotopic mouse model of pancreatic cancer and prevents the loss of body weight and muscle. It also improves physical activity including grip strength and latency to fall in tumorbearing mice. In conclusion, silibinin-induced metabolic reprogramming diminishes cell growth and cachectic properties of pancreatic cancer cells and animal models.

KW - C-Myc

KW - Cachexia

KW - Cancer metabolism

KW - Pancreatic cancer

KW - Silibinin

UR - http://www.scopus.com/inward/record.url?scp=84951204444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951204444&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5843

DO - 10.18632/oncotarget.5843

M3 - Article

C2 - 26510913

AN - SCOPUS:84951204444

VL - 6

SP - 41146

EP - 41161

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 38

ER -